Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

LUN02-50

A Phase II Trial of Gefitinib (Iressa®) Plus Celecoxib (Celebrex®) in Chemotherapy-naïve Patients with Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)

Abstracts/Posters/Presentations:

  • A. Agarwala, L. Einhorn, W. Fisher, D. Bruetman, J. McClean, D. Taber, M. Titzer, B.Juliar, T. Breen, N. Hanna. Gefitinib plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC): A Phase II Study from the Hoosier Oncology Group LUN02-50. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia

Manuscripts/Articles:

  • A.M. Moore, L.H. Einhorn, D. Estes, R. Govindan, J. Axelson, J. Vinson, T. E. Breen, M. Yu, N.H. Hanna. Gefitinib in Patients with Chemo-sensitive and Chemo-refractory Relapsed Small Cell Cancers: A Hoosier Oncology Group Phase II Trial LUN02-50. Lung Cancer (2006) 52, 93-97
  • Anuj Agarwala, William Fisher, Daniel Bruetman, John McClean, David Taber, Michael Titzer, Beth Juliar, Menggang Yu, Tim Breen, Lawrence Einhorn, Nasser Hanna. Gefitinib plus Celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group LUN02-50. J Thorac Oncol 2008;3:374-379.